NASDAQ · AMGN
Healthcare · Drug Manufacturers - General
$432.42
Down-$4.57 (-1.05%)
Updated Aug 31, 2026, 7:13 AM
SID Score
7.5/10
Composite research score
Smart Money
50/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AMGN closed at $432.42 after 20 trading sessions, up 14.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $437.89 | $437.89 | $430.72 | $432.42 | 1.74M |
| Aug 27, 2026 | $433.08 | $442.13 | $431.01 | $436.99 | 1.76M |
| Aug 26, 2026 | $441.00 | $442.885 | $438.24 | $440.34 | 2.29M |
| Aug 25, 2026 | $443.26 | $447.03 | $441.26 | $442.24 | 2.1M |
| Aug 24, 2026 | $440.31 | $445.87 | $435.51 | $443.84 | 2.46M |
| Aug 21, 2026 | $431.72 | $440.51 | $429.38 | $439.33 | 2.11M |
| Aug 20, 2026 | $435.78 | $441.34 | $431.07 | $433.73 | 2.91M |
| Aug 19, 2026 | $430.24 | $443.20 | $429.38 | $442.36 | 2.54M |
| Aug 18, 2026 | $421.64 | $427.39 | $420.72 | $425.28 | 2.59M |
| Aug 17, 2026 | $412.98 | $419.60 | $410.40 | $419.38 | 2.88M |
| Aug 14, 2026 | $413.76 | $416.03 | $410.50 | $415.21 | 2.04M |
| Aug 13, 2026 | $419.92 | $420.26 | $415.78 | $417.84 | 2.78M |
| Aug 12, 2026 | $413.31 | $418.1927 | $409.0001 | $416.18 | 2.07M |
| Aug 11, 2026 | $415.52 | $421.79 | $412.20 | $414.30 | 2.03M |
| Aug 10, 2026 | $408.46 | $417.36 | $406.42 | $417.20 | 1.96M |
| Aug 7, 2026 | $404.09 | $411.60 | $401.07 | $410.945 | 1.82M |
| Aug 6, 2026 | $413.715 | $418.40 | $401.20 | $404.85 | 2.61M |
| Aug 5, 2026 | $393.36 | $416.24 | $391.00 | $407.83 | 5.75M |
| Aug 4, 2026 | $380.755 | $390.92 | $376.02 | $390.02 | 3.62M |
| Aug 3, 2026 | $388.50 | $391.03 | $375.96 | $378.87 | 3.44M |
The latest Smart Investors Daily articles mentioning AMGN.
AMGN research
Company profile and research snapshot.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 19, 2026 | Argus Research | Buy | — |
| Aug 18, 2026 | Mizuho | Neutral | — |
| Aug 18, 2026 | Cantor Fitzgerald | Neutral | — |
| Aug 14, 2026 | Barclays | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Benzinga · Aug 25, 2026
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 14.92%. Currently, Amgen has a market capitalization of $241.16 billion.
Yahoo · Aug 21, 2026
Suddenly the Nasdaq couldn’t hold onto early gains, and you can probably guess which stocks are to blame. The Nasdaq Composite was hovering around breakeven after a wave of selling hit chips and AI infrastructure stocks. The S&P 500 was still up 0.3%.
Yahoo · Aug 21, 2026
The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.
Interpretive context generated from the platform’s current data sources.
Amgen Inc. shares closed at $432.42, reflecting a single-session decline of 2.50% per SID market data. Despite the daily pullback, the stock has demonstrated sustained upward momentum across multiple timeframes, gaining 11.55% over the past month, 28.39% over three months, and 25.19% over the trailing twelve months. The stock trades well above both its 50-day moving average of $387.89 and its 200-day moving average of $362.30, indicating a firmly established bullish trend according to Massive/Polygon technical data. The 14-day relative strength index stands at 61.5, positioning the stock in neutral-to-bullish territory without reaching overbought conditions. Amgen's beta of 0.472 underscores its defensive characteristics within the Healthcare sector, exhibiting roughly half the volatility of the broader market. Average daily trading volume registers at approximately 2.89 million shares, supporting adequate liquidity for institutional participation. The company's current market capitalization stands at approximately $209.2 billion.
Amgen Inc. currently trades at a price-to-earnings ratio of 27.13, reflecting a premium valuation relative to broader market averages, per SID market data. The PEG ratio stands at 2.72, suggesting the stock's earnings multiple exceeds its projected growth rate, as a PEG above 1.0 generally indicates a growth-adjusted premium. The price-to-book ratio registers at 24.16, which is elevated but consistent with capital-light biotechnology business models where intangible assets and intellectual property drive substantial value beyond book equity. According to SEC filings and current dividend data, Amgen offers a dividend yield of approximately 2.49%, providing meaningful income generation for shareholders within the Healthcare sector. This yield positions the company competitively among large-cap biotechnology peers, balancing capital returns with ongoing research and development investment. The $209.2 billion market capitalization reflects Amgen's standing as one of the largest independent biotechnology companies globally, commanding valuations consistent with its diversified therapeutic portfolio.
Amgen Inc. registers a composite smart money score of 50 out of 100 with a neutral overall signal, per SID market data. The institutional component scores a maximum 25 out of 25, indicating robust and sustained accumulation by large fund managers as reflected in 13F institutional filings. Insider activity scores 8.6 out of 25, with SEC Form 4 filings revealing 15 insider transactions over the past 90 days, comprising 9 purchases and 6 sales. The net buying bias among insiders suggests measured confidence from corporate officers and directors, though the activity level remains moderate relative to the stock's market capitalization. Dark pool trading activity scores 9.7 out of 25, indicating moderate levels of off-exchange institutional block trading. Congressional trading activity registers at 6.8 out of 25, reflecting limited but present interest from elected officials' disclosed portfolios. The divergence between the perfect institutional score and lower component scores in other categories produces the balanced neutral composite reading, suggesting no decisive directional conviction from aggregated smart money indicators.
Amgen Inc. has delivered a consistent pattern of earnings beats across its three most recent reported quarters, according to company earnings reports. In the most recent quarter, Amgen posted earnings per share of $6.29 against a consensus estimate of $5.60, representing an upside surprise of $0.69 or approximately 12.3%. The preceding quarter showed EPS of $5.15 versus expectations of $4.76, a $0.39 beat, while the quarter before that produced $5.29 against the $4.75 estimate, exceeding forecasts by $0.54. This streak of outperformance demonstrates the company's ability to consistently surpass analyst projections. Looking ahead, analyst estimates project EPS of approximately $4.81 for the upcoming reporting period, per consensus data. The sequential trajectory of reported earnings, ranging from $5.15 to $6.29 across recent quarters, reflects improving profitability dynamics. Investors will monitor whether the established pattern of positive earnings surprises continues in the next reporting cycle.
Recent Wall Street analyst coverage of Amgen Inc. reflects a mixed but modestly constructive consensus, per SID consensus data. In August 2026, Piper Sandler reiterated an Overweight rating, while Argus Research maintained a Buy recommendation, representing the bullish contingent among covering analysts. Conversely, Mizuho and Cantor Fitzgerald both reiterated Neutral ratings on August 18, and Barclays maintained an Equal-Weight stance on August 14, according to Wall Street analyst reports. Notably, none of the five most recent rating actions involved upgrades or downgrades, with all firms reaffirming their prior positions. This pattern suggests analyst sentiment has stabilized following the stock's 28.39% three-month rally. The split between two bullish ratings and three neutral ratings indicates that some analysts view current price levels as fairly reflecting Amgen's fundamentals after the recent advance. The absence of any Sell or Underweight ratings among recent coverage suggests a floor of institutional support, while the neutral majority implies limited expectations for further near-term multiple expansion.
The latest Smart Investors Daily articles mentioning AMGN.
